| Dr Madan Mohan Gangapuram Reddy, MD | |
|
1210 Ky Highway 36 E Ste 1d, Cynthiana, KY 41031-7490 | |
| (859) 234-1707 | |
| (859) 234-1768 |
| Full Name | Dr Madan Mohan Gangapuram Reddy |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 36 Years |
| Location | 1210 Ky Highway 36 E Ste 1d, Cynthiana, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649559592 | NPI | - | NPPES |
| 7100227130 | Medicaid | KY |
| Facility Name | Location | Facility Type |
|---|---|---|
| Montgomery General Hospital, Inc | Montgomery, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Montgomery General Hospital, Inc | 6204735269 | 30 |
News Archive
Patients living with heart failure receive palliative care significantly less often than patients with other illnesses, including cancer, despite evidence that such care improves symptom management and quality of life.
New public health research by a Purdue University professor could help shed light on how the environment can influence physical activity, especially when it comes to where people live.
Resverlogix Corp. has announced that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL.
Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, has presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.
The new study, by researchers from UNIST demonstrates a more holistic light-based treatment to nuke cancer cells instead of surgery. The results, reported in the September issue of the Journal of the American Chemical Society, could open up new avenues of research in cancer treatment.
› Verified 8 days ago
| Entity Name | Harrison Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669615233 PECOS PAC ID: 4284784067 Enrollment ID: O20090617000216 |
News Archive
Patients living with heart failure receive palliative care significantly less often than patients with other illnesses, including cancer, despite evidence that such care improves symptom management and quality of life.
New public health research by a Purdue University professor could help shed light on how the environment can influence physical activity, especially when it comes to where people live.
Resverlogix Corp. has announced that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL.
Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, has presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.
The new study, by researchers from UNIST demonstrates a more holistic light-based treatment to nuke cancer cells instead of surgery. The results, reported in the September issue of the Journal of the American Chemical Society, could open up new avenues of research in cancer treatment.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Madan Mohan Gangapuram Reddy, MD 1210 Ky Highway 36 E Ste G3, Cynthiana, KY 41031-7498 Ph: (859) 234-3605 | Dr Madan Mohan Gangapuram Reddy, MD 1210 Ky Highway 36 E Ste 1d, Cynthiana, KY 41031-7490 Ph: (859) 234-1707 |
News Archive
Patients living with heart failure receive palliative care significantly less often than patients with other illnesses, including cancer, despite evidence that such care improves symptom management and quality of life.
New public health research by a Purdue University professor could help shed light on how the environment can influence physical activity, especially when it comes to where people live.
Resverlogix Corp. has announced that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL.
Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, has presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.
The new study, by researchers from UNIST demonstrates a more holistic light-based treatment to nuke cancer cells instead of surgery. The results, reported in the September issue of the Journal of the American Chemical Society, could open up new avenues of research in cancer treatment.
› Verified 8 days ago
Dr. Gene Jason Hunt, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1210 Ky Highway 36 E, Cynthiana, KY 41031 Phone: 859-234-1707 Fax: 859-234-1768 | |
Dr. Leslie Ellen Schwindel, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1210 Ky Highway 36 E, Cynthiana, KY 41031 Phone: 592-341-7078 Fax: 859-234-1768 | |
Dr. James Pettey, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1210 Ky Highway 36 E, Suite 1d, Cynthiana, KY 41031 Phone: 859-234-1707 Fax: 859-234-1768 |